Drug Trial Radar · NCT05196373
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 7, 2021
Primary completion
Jun 30, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adult patients with hypertrophic scars 30 Subjects in Dose Escalation 20 Subjects in Dose Expansion Intrascar injection of STP705 weekly for 4 weeks
Conditions
- Hypertrophic Scar
Interventions
STP705Drug
STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of siRNA-TGF-B1 and siRNA-COX-2 in serumTime frame: 7 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 9th Hospital of Shanghai
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.